Communiqués Sequana Medical N.V.

Actions

SEQUA

BE0974340722

Marché Fermé - Euronext Bruxelles Autres places de cotation 16:57:52 05/07/2024			Varia. 5j.	Varia. 1 janv.
1,325 ^EUR	-2,21%		-5,36%	-66,88%

06/06	Sequana Medical annonce des données sur l'innocuité et la qualité de vie de l'Alfapump® qui seront présentées au congrès de l'EASL 2024	CI
03/04	Sequana Medical annonce la publication dans l'European Journal of Heart Failure de données solides issues d'études de preuve de concept de la thérapie DSR chez des patients souffrant d'insuffisance cardiaque	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Sequana Medical announces data on alfapump safety and quality of life to be presented at EASL Congress 2024	07/06	AQ
Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump	23/05	AQ
Sequana Medical N : Draft Remuneration Policy	24/04	PU
Advice of the ad hoc committee of independent directors in accordance with Article 7:179 of the Belgian Companies and Associations Code	24/04	PU
Report of the Board of Directors in accordance with Articles 7:179 and 7:197 of the Belgian Companies and Associations Code	22/04	PU
Special Report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code	22/04	PU
Sequana Medical N : Report of the Board of Directors on the annual accounts for the year ended 31 December 2023	22/04	PU
Sequana Medical N : Statutory annual accounts for the year ended 31 December 2023	22/04	PU
Sequana Medical N : Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2023	22/04	PU
Sequana Medical N : Statutory auditor’s report on the annual accounts for the year ended 31 December 2023	22/04	PU
Sequana Medical submits Premarket Approval application to US FDA for alfapump in recurrent or refractory ascites due to liver cirrhosis	29/12	AQ
Sequana Medical N : announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure	29/11	PU
Sequana Medical N : announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission	19/10/23	PU
Sequana Medical N : announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome	18/10/23	PU
Sequana Medical N : announces Extraordinary General Meeting of Shareholders on 10 November 2023	06/10/23	PU
Sequana Medical N : Special report of the Board of Directors	05/10/23	PU
Sequana Medical N : ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES	05/10/23	PU
Sequana Medical N : announces H1 2023 results and provides business update	14/09/23	PU
Sequana Medical N : 2023 Half Year Report	14/09/23	PU
Sequana Medical N : Notice of 2023 Half-year Results and Business Update	06/09/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Sequana Medical N.V.

Actions

SEQUA

BE0974340722

Communiqués

Filtres